{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:54Z","timestamp":1792007754841,"version":"4.4.0"},"reference-count":33,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":62,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1 I01 CX000167-01"],"award-info":[{"award-number":["1 I01 CX000167-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>While vitamin E has shown to improve nonalcoholic steatohepatitis (NASH) in patients without diabetes, information on patients with type 2 diabetes mellitus (T2DM) is lacking. The aim of this study was to determine whether vitamin E, alone or combined with pioglitazone, improves histology in patients with T2DM and NASH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This was a proof-of-concept, randomized, double-blind, placebo-controlled trial conducted from 2010 to 2016. Patients with T2DM and biopsy-proven NASH (n = 105) were randomized to vitamin E 400 IU b.i.d., vitamin E 400 IU b.i.d. plus pioglitazone 45 mg\/day, or placebo. Eighty-six patients completed the 18-month study. The primary end point was a two-point reduction in the nonalcoholic fatty liver disease activity score from two different parameters, without worsening of fibrosis. Secondary outcomes were resolution of NASH without worsening of fibrosis, individual histological scores, and metabolic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>More patients on combination therapy achieved the primary outcome versus placebo (54% vs. 19%, P = 0.003) but not with vitamin E alone (31% vs. 19%, P = 0.26). Both groups showed improvements in resolution of NASH compared with placebo (combination group: 43% vs. 12%, P = 0.005; vitamin E alone: 33% vs. 12%, P = 0.04). While steatosis assessed by histology improved with combination therapy (P &amp;lt; 0.001) and vitamin E alone (P = 0.018), inflammation (P = 0.018) and ballooning (P = 0.022) only improved with combination therapy. No improvement in fibrosis was observed in any group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In this proof-of-concept study, combination therapy was better than placebo in improving liver histology in patients with NASH and T2DM. Vitamin E alone did not significantly change the primary histological outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-0167","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T12:18:25Z","timestamp":1563365905000},"page":"1481-1488","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":288,"title":["Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial"],"prefix":"10.2337","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct01002547","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-4396","authenticated-orcid":false,"given":"Fernando","family":"Bril","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Biernacki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilaxmi","family":"Kalavalapalli","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Lomonaco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreevidya K.","family":"Subbarayan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fermin","family":"Tio","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Suman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Malcom Randall VA Medical Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly K.","family":"Orsak","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Hecht","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Audie L. Murphy Memorial VA Hospital, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"},{"name":"Division of Endocrinology, Diabetes and Metabolism, Malcom Randall VA Medical Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"2022031300202003200_B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022031300202003200_B2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"2022031300202003200_B3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"2022031300202003200_B4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"key":"2022031300202003200_B5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2022031300202003200_B6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"Diabetologia"},{"key":"2022031300202003200_B7","first-page":"367","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume-title":"Gastroenterology","author":"Vilar-Gomez","year":"2015"},{"key":"2022031300202003200_B8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"2022031300202003200_B9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031300202003200_B10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"2022031300202003200_B11","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"key":"2022031300202003200_B12","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"2022031300202003200_B13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"2022031300202003200_B14","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031300202003200_B15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022031300202003200_B16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022031300202003200_B17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","article-title":"Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis","volume":"4","author":"Dufour","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022031300202003200_B18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/apt.15163","article-title":"Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside","volume":"49","author":"Sookoian","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022031300202003200_B19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"2022031300202003200_B20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"key":"2022031300202003200_B21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"2022031300202003200_B22","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"2022031300202003200_B23","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1152\/ajpendo.00023.2018","article-title":"Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis","volume":"315","author":"Kalavalapalli","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031300202003200_B24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"2022031300202003200_B25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2022031300202003200_B26","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology"},{"key":"2022031300202003200_B27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"2022031300202003200_B28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031300202003200_B29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"2022031300202003200_B30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","article-title":"NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk","volume":"34","author":"Ballestri","year":"2017","journal-title":"Adv Ther"},{"key":"2022031300202003200_B31","first-page":"1147","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume-title":"Gastroenterology","author":"Ratziu","year":"2016"},{"key":"2022031300202003200_B32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2016.02.044","article-title":"Regulatory science and drug approval for alcoholic and nonalcoholic steatohepatitis","volume":"150","author":"Sanyal","year":"2016","journal-title":"Gastroenterology"},{"key":"2022031300202003200_B33","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-0167","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/8\/1481\/529265\/dc190167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/8\/1481\/529265\/dc190167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:33:30Z","timestamp":1647142410000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/8\/1481\/36160\/Role-of-Vitamin-E-for-Nonalcoholic-Steatohepatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,21]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-0167","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]}}}